Last Updated: 01/01/2025

RTS,S/AS01 pediatric indication

Objectives

Partner Institutions

PATH, United States
GlaxoSmithKline (GSK), United Kingdom

SHARE

Related Resources

Full Evidence Report on the RTS,S/AS01 Malaria Vaccine
Report
Full Evidence Report on the R21/Matrix-M Malaria Vaccine
Report
Framework for the allocation of limited malaria vaccine supply
Guidance & Strategy

Related Projects

Jan 2024 —
Jun 2024
Baseline immune signatures as predictors of RTS,S/AS01 antimalarial vaccine immunogenicity and efficacy by integrative analysis of scCITE-seq and scATAC-seq data
Yale University, United States
Apr 2023 —
Mar 2027

$4.84M

The impact of a combination of the RTS,S/AS01E malaria vaccine and perennial chemoprevention of malaria in Ghanaian children (MalVac-PMC)
Kintampo Health Research Centre (KHRC), Ghana; London School of Hygiene and Tropical Medicine (LSHTM), United Kingdom
Nov 2020 —
Aug 2022
Efficacy of delayed, fractional dose RTS,S/AS01E malaria vaccine in adults in Kenya treated with artemisinin combination therapy plus primaquine
GlaxoSmithKline (GSK), United Kingdom; PATH, United States; Kenya Medical Research Institute (KEMRI), Kenya
SHARE